Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy

By Mori Kiyoshi   Kamiyama Yukari   Kondo Tetsuro   Kano Yasuhiko   Kodama Tetsuro  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 189-195

Springer Publishing Company

Access to resources Recommend Favorite

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

By  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1133-1133

Oxford University Press

Access to resources Recommend Favorite

Five-Year Survival after Second-Line Cisplatin-Based Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

By Recio F.O.   Piver M.S.   Hempling R.E.   Driscoll D.L.  

Gynecologic Oncology, Vol. 68, Iss. 3, 1998-03 ,pp. : 267-273

Elsevier

Access to resources Recommend Favorite

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

By Arrieta Oscar  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 300-306

Humana Press, Inc

Access to resources Recommend Favorite